Aerobic vs Neuromuscular Exercise for Knee OA
Key facts
- Who runs it
- Frederiksberg University Hospital
- Where
- Denmark1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 150 people enrolled
- Started
- 23 Feb 2024
- Ended
- 12 Jun 2026
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- eHIIT
- NEMEX-e
- Record updated
- 16 June 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (20)Hide the full registry criteria
Who can take part
- Age ≥18- years
- Diagnosis of tibiofemoral knee OA according to the American College of Rheumatology criteria
- Radiographically confirmed diagnosis of tibiofemoral OA based on radiographs not older than 6 months
- Average knee pain level ≥ 4 (0=No pain and 10=Worst pain) over the past week (7 days)
- At least one of following risk factors for development of cardiovascular disease:; Body mass index ≥ 30 kg/m2; Hypertension (or in treatment of): Systolic ≥ 135 and/or diastolic ≥ 85 mm Hg; Elevated HbA1c (or in treatment of): ≥ 130.7 mg/dL (44 mmol/mol); Elevated Triglycerides (or in treatment of): ≥ 150 mg/dL (1.7 mmol/L); Elevated Cholesterol (or in treatment of) (Low density lipides, LDL): LDL ≥ 54 mg/dL (3.0 mmol/L)
Who cannot take part
- Planned weight loss (non-pharmacological, pharmacological, and surgical) during study participation
- Scheduled surgery during study participation
- Treatment with biological medication
- Known current cancer
- Insulin dependent type 1 or type 2 diabetes
- Psoriatic, rheumatoid, or gouty arthritis disease
- Generalized pain syndromes such as fibromyalgia
- Lumbar or cervical nerve root compression syndromes
- Any other condition or impairment that, in the opinion of the investigator, makes a potential participant unsuitable for participation or which obstruct participation, such as a large knee joint effusion, uncontrolled diabetes/hypertension, psychiatric or cognitive disorders, language barriers, or opiate dependency
- Contraindication to exercise (e.g., resting systolic blood pressure > 200 or diastolic blood pressure > 115, acute or reoccurring chest pain)
- Unstable body weight the last 3 months (gain/loss outside +/- 5 kg)
- Major cardiovascular event within the last 5 years
- Impairments that prevent performance in high intensity aerobic exercise
- Current or planned participation in other health research intervention studies
- Pregnant/considering pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study aims to compare the effects of an education and High Intensity Interval Training program (eHIIT) with the widely used Neuromuscular Exercise and education program (NEMEX-e) on knee OA symptoms and risk factors for cardiovascular disease in people with knee OA and at least one risk factor for developement of cardiovascular disease. The main research questions the study aims to answer are:
Read full original descriptionShow less
* Is the eHIIT program better than the NEMEX-e program for reducing the risk of cardiovascular disease? * Are the two programs equally good at providing improvement in knee symptoms?
The 2 groups in the trial
- Education and High Intensity Interval Training (eHIIT)Existing treatment, for comparison
1 educational session lasting 1 hour. 12 weeks of supervised High Intensity Interval Training (HIIT) 3 times/week.
Treatment: eHIIT
- Neuromuscular exercise and education program (NEMEX-e)Existing treatment, for comparison
2 educational sessions lasting 1 hour each. 8 weeks of supervised Neuromuscular Exercise 2 times/week.
Treatment: NEMEX-e
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Comparative Effectiveness of High-intensity Aerobic Exercise and Biomechanical Neuromuscular Exercise for Treatment of Knee Osteoarthritis: A Randomised Open Label Trial
- Record updated
- 16 June 2026